相关实验视频
Updated: Jul 15, 2025

08:25
Identification of Circular RNAs using RNA Sequencing
Published on: November 14, 2019
12.3K
对阿尔茨海默病的新视角:微RNA和循环RNA
Shahidee Zainal Abidin1,2, Nurul Asykin Mat Pauzi1, Nur Izzati Mansor3
1Faculty of Science and Marine Environment, Universiti Malaysia Terengganu, Terengganu, Malaysia.
Frontiers in genetics
|October 4, 2023
概括
微RNAs (miRNAs) 和循环RNAs (circRNAs) 都与阿尔茨海默氏病 (AD) 的发病有关. 本综述研究了阿尔茨海默病患者的改变miRNA表达和circRNAs作为潜在生物标志物和治疗点的新兴作用.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 微RNAs (miRNAs) 是阿尔茨海默病 (AD) 发病过程中的关键调节者,影响Aβ代谢,陶酸化,神经炎症和突触功能.
- miRNA活动是由诸如亚细胞局部化,miRNA-mRNA丰富性和结合亲和力等因素调节的,外细胞miRNA通过外体运输.
- 循环RNAs (circRNAs) 是一种新型的非编码RNAs类,通过与miRNAs的相互作用来调节基因表达,尽管它们在AD中的精确机制正在研究中.
研究的目的:
- 在阿尔茨海默病 (AD) 患者中,全面审查各种来源 (血液,外体,中枢神经液,大脑) 的miRNA表达的变化.
- 探索循环RNAs (circRNAs) 在AD病变发生过程中的新兴作用.
- 讨论miRNAs和circRNAs作为诊断生物标志物和AD治疗点的潜力.
主要方法:
- 在阿尔茨海默病中调查miRNA表达特征的研究的文献综述.
- 对循环RNA在AD病理学的参与研究的分析.
- 综合目前对神经退行性疾病中miRNA和circRNA功能和相互作用的理解.
主要成果:
- 在外周血液,外体,脑脊液和AD患者的大脑组织中观察到miRNA表达的显著变化.
- 新出现的证据表明,circRNAs在AD病变发生过程中发挥作用,可能是通过与miRNAs的相互作用.
- 阿尔茨海默病理的复杂性对基于miRNA的诊断提出了挑战,需要进一步的研究.
结论:
- miRNAs是AD的关键参与者,具有改变的表达模式,在不同的生物流体和组织中提供诊断潜力.
- circRNAs是研究了解AD机制和开发新型治疗策略的一个有前途的领域.
- 进一步研究miRNA和circRNA配置文件对于推动AD诊断和治疗至关重要.
相关概念视频
MicroRNAs
21.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.4K
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
RNA Interference
26.1K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.1K
Experimental RNAi
6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K

